BR112012031290A2 - composição fluidificável injetável compreendendo buprenorfina - Google Patents

composição fluidificável injetável compreendendo buprenorfina

Info

Publication number
BR112012031290A2
BR112012031290A2 BR112012031290A BR112012031290A BR112012031290A2 BR 112012031290 A2 BR112012031290 A2 BR 112012031290A2 BR 112012031290 A BR112012031290 A BR 112012031290A BR 112012031290 A BR112012031290 A BR 112012031290A BR 112012031290 A2 BR112012031290 A2 BR 112012031290A2
Authority
BR
Brazil
Prior art keywords
buprenorphine
injectable
fluidizable
composition
delivery system
Prior art date
Application number
BR112012031290A
Other languages
English (en)
Inventor
Andrew Watkins
Mingxing Zhou
Richard L Norton
Original Assignee
Rb Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012031290(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rb Pharmaceuticals Ltd filed Critical Rb Pharmaceuticals Ltd
Publication of BR112012031290A2 publication Critical patent/BR112012031290A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição fluidificável injetável compreendendo buprenorfina. esta divulgação se refere a um sistema de distribuição de liberação sustentada de biprenofina para o tratamento de condições melhoradas por compostos de buprenorfina. o sistema de distribuição de liberação sustentada inclui uma composição fluida contendo uma suspensão de buprenorfina, um mtabólico ou um pró-fármaco da mesma.
BR112012031290A 2010-06-08 2011-06-06 composição fluidificável injetável compreendendo buprenorfina BR112012031290A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions

Publications (1)

Publication Number Publication Date
BR112012031290A2 true BR112012031290A2 (pt) 2016-11-01

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012031290A BR112012031290A2 (pt) 2010-06-08 2011-06-06 composição fluidificável injetável compreendendo buprenorfina

Country Status (31)

Country Link
US (1) US8921387B2 (pt)
EP (3) EP3360538B1 (pt)
JP (2) JP5986072B2 (pt)
KR (1) KR101865689B1 (pt)
CN (1) CN103079544B (pt)
AU (1) AU2011263478B2 (pt)
BR (1) BR112012031290A2 (pt)
CA (1) CA2801676C (pt)
CL (1) CL2012003462A1 (pt)
CO (1) CO6670529A2 (pt)
CY (1) CY1120761T1 (pt)
DK (2) DK3360538T3 (pt)
ES (2) ES2656938T3 (pt)
FI (1) FI3360538T3 (pt)
GB (2) GB2513267B (pt)
HR (1) HRP20180118T1 (pt)
HU (1) HUE038275T2 (pt)
IL (2) IL223488A (pt)
LT (1) LT2579874T (pt)
MX (1) MX339209B (pt)
MY (1) MY171625A (pt)
NO (1) NO2579874T3 (pt)
NZ (1) NZ604026A (pt)
PL (1) PL2579874T3 (pt)
PT (1) PT2579874T (pt)
RS (1) RS56820B1 (pt)
RU (1) RU2607498C2 (pt)
SG (1) SG186200A1 (pt)
SI (1) SI2579874T1 (pt)
WO (1) WO2011154724A2 (pt)
ZA (1) ZA201209233B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
AR092820A1 (es) 2012-04-17 2015-05-06 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
WO2014016428A1 (en) * 2012-07-26 2014-01-30 Camurus Ab Opioid formulations
PE20150672A1 (es) * 2012-07-26 2015-05-21 Camurus Ab Formulaciones de opioides
EP2931253A1 (en) * 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
WO2014143635A1 (en) * 2013-03-15 2014-09-18 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
ES2837149T3 (es) * 2014-04-21 2021-06-29 Heron Therapeutics Inc Composiciones de un poliortoéster y un excipiente de ácido orgánico
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
CN114886899B (zh) 2014-04-21 2024-02-13 赫伦治疗有限公司 长效聚合物输送系统
CN106458850B (zh) 2014-04-28 2019-09-17 奥佛麦德公司 通过酚羟基连接的药物活性二聚体
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations
WO2016071767A1 (en) * 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
EP3331495B1 (en) 2015-08-03 2020-11-04 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
HRP20231453T1 (hr) 2015-11-16 2024-03-01 Medincell S.A. Postupak za morseliranje i/ili usmjeravanje farmaceutski aktivnih sastojaka na sinovijalno tkivo
HRP20230062T8 (hr) * 2016-09-13 2023-04-14 Alar Pharmaceuticals Inc. Formulacije buprenorfina sa produženim oslobađanjem
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2018229551A2 (en) 2017-06-16 2018-12-20 Indivior Uk Limited Methods to treat opioid use disorder
JP2021511326A (ja) 2018-01-22 2021-05-06 フォアシー ファーマシューティカルズ シーオー．，リミテッド ブプレノルフィンの徐放送達のための薬学的組成物
US20210060316A1 (en) * 2019-08-30 2021-03-04 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
ATE209907T1 (de) 1994-04-08 2001-12-15 Atrix Lab Inc Flüssige mittel zur wirkstoffabgabe
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
ES2665999T3 (es) * 2002-05-31 2018-04-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para la liberación sostenida de buprenorfina
RU2355385C2 (ru) * 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
AU2004219595A1 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
RS53890B1 (en) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. STABILIZED POLYMER DELIVERY SYSTEM
PT2115029E (pt) 2007-02-15 2015-10-26 Tolmar Therapeutics Inc Poli-(lactido/glicolido) de efeito de libertação imediata reduzido e métodos de produção de polímeros
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
MX2012014335A (es) 2013-03-05
US8921387B2 (en) 2014-12-30
ES2939612T3 (es) 2023-04-25
CO6670529A2 (es) 2013-05-15
MX339209B (es) 2016-04-15
ZA201209233B (en) 2014-04-30
GB201009549D0 (en) 2010-07-21
GB2481018B (en) 2015-03-18
EP4218720A1 (en) 2023-08-02
JP2013533230A (ja) 2013-08-22
HRP20180118T1 (hr) 2018-03-09
CA2801676A1 (en) 2011-12-15
GB201413064D0 (en) 2014-09-03
IL254417A0 (en) 2017-11-30
JP2016155865A (ja) 2016-09-01
RU2607498C2 (ru) 2017-01-10
NZ604026A (en) 2015-01-30
DK3360538T3 (da) 2023-03-06
RS56820B1 (sr) 2018-04-30
EP2579874B1 (en) 2018-01-10
WO2011154724A2 (en) 2011-12-15
JP5986072B2 (ja) 2016-09-06
CN103079544A (zh) 2013-05-01
CY1120761T1 (el) 2019-12-11
CA2801676C (en) 2018-08-07
LT2579874T (lt) 2018-02-12
PL2579874T3 (pl) 2018-05-30
GB2513267A (en) 2014-10-22
RU2012157244A (ru) 2014-07-20
JP6251774B2 (ja) 2017-12-20
DK2579874T3 (da) 2018-01-29
PT2579874T (pt) 2018-01-29
AU2011263478A1 (en) 2013-01-10
SI2579874T1 (en) 2018-03-30
GB2513267B (en) 2015-03-18
AU2011263478B2 (en) 2015-01-22
CL2012003462A1 (es) 2013-04-01
SG186200A1 (en) 2013-01-30
MY171625A (en) 2019-10-21
WO2011154724A3 (en) 2012-07-12
HUE038275T2 (hu) 2018-10-29
FI3360538T3 (fi) 2023-03-22
EP3360538A1 (en) 2018-08-15
NO2579874T3 (pt) 2018-06-09
KR20130135026A (ko) 2013-12-10
WO2011154724A9 (en) 2012-08-16
GB2481018A (en) 2011-12-14
IL223488A (en) 2017-10-31
EP2579874A2 (en) 2013-04-17
EP3360538B1 (en) 2023-02-15
CN103079544B (zh) 2017-06-09
US20130210853A1 (en) 2013-08-15
ES2656938T3 (es) 2018-03-01
KR101865689B1 (ko) 2018-06-08

Similar Documents

Publication Publication Date Title
BR112012031290A2 (pt) composição fluidificável injetável compreendendo buprenorfina
CL2015000177A1 (es) Composición para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina
BR112014010183A2 (pt) composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou uma condição de doença mediada por uma fgfr cinase
PE20150887A1 (es) Compuestos de benceno sustituidos
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
CY1118307T1 (el) Συνθεσεις που περιλαμβανουν βουπρενορφινη (buprenorphine)
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
GT201400111A (es) Triazolopiridinas sustituidas
MX2012015188A (es) Composiciones de liberacion controlada con efecto de alimentos reducido.
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
GT201300009A (es) Derivados de tetrahidro-pirido-pirimidina
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
HN2012000182A (es) Formulacion farmaceutica
MX358499B (es) Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40).
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
BR112013031712A2 (pt) composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
HK1194302A1 (zh) 紫檀茋在製造用於治療、緩解或預防焦慮的藥物組合物中的應用
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
BR112014025041B8 (pt) Composição farmacêutica
UY33278A (es) Pirimidinas sustituidas como antagonistas del receptor de la protaglandina d2
BRPI1010300A2 (pt) processos para a preparação de um composto, para perparar dronedarone, ou um sal do mesmo, e para preparar uma formulação farmacêutica.
BR112014001015A2 (pt) agente de cura para composições de cura por umidade

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: INDIVIOR UK LIMITED. (GB)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]